BioMarin to initiate BMN-111 Stage 1 trial in achondroplasia BioMarin Pharmaceutical Inc. announced today that the Investigational New Medication software for BMN-111, an analog of C-type Natriuretic Peptide , for achondroplasia is active. ‘BMN-111 offers demonstrated benefits in moderately and severely affected pet versions and has been proven to market bone growth also in normal pets,’ mentioned Hank Fuchs, M.D.’ The principal objective of the Stage 1 trial is normally to assess the protection and tolerability of solitary and multiple dosages of BMN-111 in normal adult healthful volunteers up to the utmost tolerated dose.They will send the sample to Athena Diagnostics for screening to identify mutations on the FHL1 gene. Genetic counsellors will help the physician to interpret the total results for your client and family members, to advise whether family members and offspring are at threat of inheriting the gene. Linked to FHL1 gene ‘Our check is for a particular muscles disorder that was lately identified. The disorder, which we call X-linked myopathy with postural muscle mass atrophy , is probably the dozens of muscular dystrophies and other like conditions with similar symptoms.